Meeting
2022 ASCO Annual Meeting
Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.
Authors
Nisha Joseph
Emory University, Winship Cancer Institute, Atlanta, GA
Nisha Joseph , Craig C. Hofmeister , Leonard T. Heffner , Vikas Anand Gupta , Jonathan L. Kaufman , Madhav V. Dhodapkar , Sagar Lonial , Ajay K. Nooka , Lawrence Boise
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 8062)
DOI
10.1200/JCO.2022.40.16_suppl.8062
Abstract #
8062
Poster Bd #
485
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Updated survival with extended follow-up on patients with newly diagnosed multiple myeloma treated with lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy and a risk-stratified maintenance approach.
First Author: Rujul H Parikh
Poster
2022 ASCO Annual Meeting
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
First Author: Brittany K. Ragon
First Author: George Somlo
Poster
2014 ASCO Annual Meeting
![MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.](https://d201v5jt9ylckg.cloudfront.net/144/8608/96164/96164_poster_pv.jpg)
MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) in lenalidomide (LEN)-refractory and proteasome inhibitor (PI)-exposed myeloma.
First Author: Paul G. Richardson